BRAF and non-small cell lung carcinoma: We did not see a significant difference in HR+ and HR- NSCLC in receptor tyrosine-protein kinase erbB-2 (ERBB2) and v-raf murine sarcoma oncogene homolog B1 (BRAF) mutations in our population (Table 5, Figures 2D, E).